MBCQ

MBCQ is a potent and selective cGMP-specific phosphodiesterase (PDE V; PDE5) inhibitor with an IC50 of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC50s>100 μM) . MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE[1][2][3].

Product Specifications

CAS Number

[150450-53-6]

Product Name Alternative

SMP 114

UNSPSC

12352005

Hazard Statement

H413

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/mbcq.html

Purity

99.80

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

ClC1=CC2=C(N=CN=C2NCC3=CC4=C(C=C3)OCO4)C=C1

Molecular Formula

C16H12ClN3O2

Molecular Weight

313.74

Precautions

H413

References & Citations

[1]Y Takase, et al. Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J Med Chem. 1994 Jun 24;37 (13) :2106-11.|[2]Jeffery D MacPherson, et al. Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation J Pharmacol Exp Ther. 2006 Apr;317 (1) :188-95.|[3]Takeharu Kaneda, et al. Lack of cyclic nucleotide regulation of MBCQ-induced relaxation of rat ileal smooth muscle. J Smooth Muscle Res. 2003 Jun;39 (3) :47-54.